Glaucoma Research Foundation

Steel and the Glaucoma Research Foundation have a relationship spanning over a decade.

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

Andrew G. Iwach, MD, recounts two personal life experiences that underscore the significance of patient-centered care in glaucoma management.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

Joseph Panarelli, MD, sat down with David Hutton of Ophthalmology Times to discuss the panel he moderated at the Glaucoma 360 meeting held in San Francisco, about innovations in glaucoma drugs, and drug delivery.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, highlight the 13th annual Glaucoma 360 New Horizons Forum, held this year at the Westin St. Francis San Francisco on Union Square.

Tonian McDonald shares her story during the Glaucoma 360 New Horizons Forum at the Westin St. Francis Hotel in San Francisco to recount her journey as a glaucoma patient.

Hoskins was a pioneer and leader in the field of ophthalmology and glaucoma, and served as executive vice president of the American Academy of Ophthalmology, founding director and Director Emeritus of the Glaucoma Research Foundation, and a founding director of the American Glaucoma Society.

The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.

Sharing, learning, networking, collaborating

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, share insights into the formation of the Glaucoma Research Foundation and what makes Glaucoma 360 such a unique conference.

Oluwatosin U. Smith, MD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Glaucoma Management Lessons Learned from a Pandemic."

Ruth Williams, MD, explained the importance of hypotension in glaucoma and its potential as a modifiable risk factor at the 27th annual Glaucoma Symposium during Glaucoma 360 at the Westin St. Francis San Francisco on Union Square.

Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.

L. Jay Katz, MD, provides some key takeaways from his Glaucoma 360 2023 presentation, "Steroid Induced Glaucoma Management."

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

According to the Glaucoma Research Foundation, the collaborative research program will explore some of the common characteristics of glaucoma, Alzheimer’s.

Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

Results from the study were presented by Russell Tait, PhD, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California

During the Glaucoma 360 New Horizons Forum at the Grand Hyatt San Francisco at Union Square, several speakers discussed the latest advances in technology.

Oluwatosin U. Smith, MD, associate professor in the Department of Ophthalmology, University of Texas Southwestern, Dallas, speaks with Ophthalmology Times'® Sheryl Stevenson on the highlights of her presentation exploring remote monitoring of glaucoma and the future of virtual care on the whole.